Literature DB >> 23215541

Contact lenses: promising devices for ocular drug delivery.

Ana Guzman-Aranguez1, Basilio Colligris, Jesús Pintor.   

Abstract

In the ocular pharmacology market, there is a noteworthy unmet demand for more efficacious delivery of ocular therapeutics. Contact lenses are emerging as an alternative ophthalmic drug delivery system to resolve the drawbacks of the conventional topical application methods. Thus, contact lenses drug delivery systems have been developed to provide an increased residence time of the drug at the surface of the eye leading to enhanced bioavailability and more convenient and efficacious therapy. Several research groups have already explored the feasibility and potential of contact lenses loading conventional drugs used to treat anterior eye disorders. Drug incorporation to the lens body is achieved with techniques, like simple soaking, inclusion of drug-loaded colloidal nanoparticles, or molecular imprinting. Regardless of the technique used, key properties of the contact lens, such as transparency and oxygen permeability, should be preserved. In this article, we reviewed the different techniques used for drug delivery through contact lenses, analyzing their advantages and disadvantages, and focused on articles describing contact lens-based ophthalmic drug delivery systems with significant potential to use in ocular therapeutics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23215541     DOI: 10.1089/jop.2012.0212

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  18 in total

Review 1.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

Review 2.  Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.

Authors:  A Guzman-Aranguez; P Loma; J Pintor
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

3.  Contact lenses: new devices for nucleotide delivery in ocular pathologies.

Authors:  Jesús Pintor
Journal:  Purinergic Signal       Date:  2014-08-20       Impact factor: 3.765

4.  Extended release of ketotifen from silica shell nanoparticle-laden hydrogel contact lenses: in vitro and in vivo evaluation.

Authors:  Furqan A Maulvi; Mayurkumar A Mangukiya; Prachi A Patel; Rutvi J Vaidya; Akshay R Koli; Ketan M Ranch; Dinesh O Shah
Journal:  J Mater Sci Mater Med       Date:  2016-05-13       Impact factor: 3.896

Review 5.  Nanoparticles for drug delivery to the anterior segment of the eye.

Authors:  Dileep R Janagam; Linfeng Wu; Tao L Lowe
Journal:  Adv Drug Deliv Rev       Date:  2017-04-06       Impact factor: 15.470

6.  Dexamethasone diffusion across contact lenses is inhibited by Staphylococcus epidermidis biofilms in vitro.

Authors:  Kimberly M Brothers; Amy C Nau; Eric G Romanowski; Robert M Q Shanks
Journal:  Cornea       Date:  2014-10       Impact factor: 2.651

7.  Bimatoprost Imprinted Silicone Contact Lens to Treat Glaucoma.

Authors:  Feng Yan; Yanxia Liu; Shulan Han; Qingsong Zhao; Nannan Liu
Journal:  AAPS PharmSciTech       Date:  2020-01-13       Impact factor: 4.026

8.  In vivo drug delivery via contact lenses: The current state of the field from origins to present.

Authors:  Liana D Wuchte; Stephen A DiPasquale; Mark E Byrne
Journal:  J Drug Deliv Sci Technol       Date:  2021-02-18       Impact factor: 5.062

9.  A Drug Delivery System for Administration of Anti-TNF-α Antibody.

Authors:  Marie-Claude Robert; Mathieu Frenette; Chengxin Zhou; Yueran Yan; James Chodosh; Frederick A Jakobiec; Anna M Stagner; Demetrios Vavvas; Claes H Dohlman; Eleftherios I Paschalis
Journal:  Transl Vis Sci Technol       Date:  2016-03-11       Impact factor: 3.283

Review 10.  Ophthalmic Drug Delivery Systems for Antibiotherapy-A Review.

Authors:  Marion Dubald; Sandrine Bourgeois; Véronique Andrieu; Hatem Fessi
Journal:  Pharmaceutics       Date:  2018-01-13       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.